Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Frank Morich

At a glance: Frank Morich is Director at Perspective Therapeutics (CATX). Their latest SEC Form 4, filed Nov 17, 2026, reported a purchase of $14K. On file: 2 purchase lines ($29K) and 0 sale lines ($0).

Disclosed holdings: about $22K of CATX stock: 30,000 shares reported on their latest Form 4 (filed Nov 17, 2026), valued at the Nov 20, 2026 close of $0.75. This counts only CATX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Perspective Therapeutics, Inc. (CATX)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys−$7K
Total bought / sold$29K / $0

Frank Morich's InsiderPrint

3 trades from SEC Form 4 filings, 2022 to 2026, drawn as one fingerprint.

InsiderPrint of Frank Morich: 3 trades, 2022 to 20262022: 1 buy, 0 sales2023: 0 buys, 0 sales2024: 0 buys, 0 sales2025: 0 buys, 0 sales2026: 2 buys, 0 sales

Reading this print: Almost only buys, trading about once a year, typically $15K a trade; often buys after the stock has fallen 15% or more.

  • Bump outward: a purchase (3)
  • Dent inward: a sale (0)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. David ColpmanDirector · ELUT · 100% match
  2. Richard J. DalyDirector · AQST · 100% match
  3. Matthew FergusonCFO · ELUT · 99% match
  4. William B. MintzSvp, Chief Strategy Officer · CTEV · 98% match
  5. Kirsten CastilloDirector · ACVA · 98% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2022

From the SEC's insider data sets: each open-market buy by Frank Morich, matched to how the stock did over the next 90 days against the S&P 500.

0 of 1 buy beat the S&P 500 (0%), median -24.5% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
CUEMay 31, 2022-24.5%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Nov 17SEC CATXPerspective Therapeutics, Inc.First buyStake +100% Buy 15,00030,000 held (+100%) $0.94 $14K -20.2%
Nov 16SEC CATXPerspective Therapeutics, Inc.First buyNew position Buy 15,000new position $1.00 $15K -25.1%
  • Buy

    Director Frank Morich bought $14K of CATX at $0.94 — raises the stake by 100%.

  • Buy

    Director Frank Morich bought $15K of CATX at $1.00 — first open-market purchase in our records; opens a new position.

Follow Frank Morich

Get one email when Frank Morich files a new purchase or sale. Free.

At most one email a day about Frank Morich, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.